9 results match your criteria: "Los Angeles) Transplant and Liver Cancer Centers[Affiliation]"
Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium.
Liver Transpl
July 2023
Department of Surgery, David Geffen School of Medicine at UCLA, Dumont-UCLA (University of California, Los Angeles) Transplant and Liver Cancer Centers, Los Angeles, California, USA.
Article Synopsis
- - The study focuses on predicting the risk of hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) using data from over 4,900 patients, emphasizing the need for personalized assessment due to high recurrence rates.
- - Researchers developed the RELAPSE score, which utilizes clinicopathological and radiological factors, validated through advanced statistical and machine learning methods, to enhance the accuracy of recurrence predictions in HCC patients post-LT.
- - Key independent predictors of HCC recurrence identified include alpha-fetoprotein levels, tumor size, and vascular invasion, with a 5-year recurrence rate of 12.5% and a more robust predictive model achieved through machine learning techniques.
Outcomes in liver transplant recipients with nonalcoholic fatty liver disease-related HCC: results from the US multicenter HCC transplant consortium.
Liver Transpl
January 2023
Department of Surgery, Dumont-UCLA (University of California, Los Angeles) Transplant and Liver Cancer Centers, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
NAFLD will soon be the most common indication for liver transplantation (LT). In NAFLD, HCC may occur at earlier stages of fibrosis and present with more advanced tumor stage, raising concern for aggressive disease. Thus, adult LT recipients with HCC from 20 US centers transplanted between 2002 and 2013 were analyzed to determine whether NAFLD impacts recurrence-free post-LT survival.
View Article and Find Full Text PDFAre Current National Review Board Downstaging Protocols for Hepatocellular Carcinoma Too Restrictive?
J Am Coll Surg
April 2022
From the Division of Abdominal Organ Transplantation, Department of Surgery, Washington University School of Medicine, Saint Louis, MO (Ahmed, Vachharajani, Chapman, Doyle).
Background: Liver transplantation (LT) is an effective strategy for patients with unresectable hepatocellular carcinoma (HCC). To qualify for standardized LT model for end-stage liver disease exception points, the United Network for Organ Sharing National Liver Review Board (NLRB) requires that the presenting and final HCC tumor burden be within the University of California San Francisco criteria, which were recently expanded (within expanded UCSF [W-eUCSF]). Current NLRB criteria may be too restrictive because it has been shown previously that the initial burden does not predict LT failure when tumors downstage to UCSF.
View Article and Find Full Text PDFPosttransplant Outcomes in Older Patients With Hepatocellular Carcinoma Are Driven by Non-Hepatocellular Carcinoma Factors.
Liver Transpl
May 2021
School of Medicine and Division of Gastroenterology and Hepatology Stanford University Stanford CA Division of Gastroenterology and Hepatology Stanford University School of Medicine Stanford CA Department of Medicine Stanford University Stanford CA Department of Surgery, Multi-Organ Transplantation Stanford University School of Medicine Stanford CA Dumont-UCLA (University of California, Los Angeles) Transplant and Liver Cancer Centers, Department of Surgery David Geffen School of Medicine at UCLA Los Angeles CA Recanati/Miller Transplantation Institute Mount Sinai Medical Center New York NY Annette C. and Harold C. Simmons Transplant Institute Baylor University Medical Center Dallas TX Department of Surgery, Division of Intra-Abdominal Transplantation Loyola University of Chicago, Stritch School of Medicine Maywood IL Department of Transplantation Mayo Clinic Jacksonville FL Division of Gastroenterology and Hepatology Penn Transplant InstituteUniversity of Pennsylvania Philadelphia PA Center for Liver Disease and Transplantation Columbia University Medical Center, NY Presbyterian Hospital New York NY Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery Weill Cornell Medical College New York NY Thomas E. Starzl Transplantation Institute University of Pittsburgh Medical Center Pittsburgh PA Section of TransplantationDepartment of Surgery Washington University in St. Louis St. Louis MO Cleveland Clinic Foundation Cleveland OH Division of Transplant SurgeryDepartment of Surgery University of Colorado School of Medicine Denver CO Division of Transplant Surgery Massachusetts General HospitalHarvard Medical School Boston MA Sherrie & Alan Conover Center for Liver Disease & Transplantation Houston Methodist Hospital Houston TX Department of Surgery University of Nebraska Medical Center Omaha NE Division of Transplantation and Hepatobiliary SurgeryDepartment of Surgery University of California, San Diego San Diego CA Department of Surgery Duke University Medical Center Durham NC Division of Transplant SurgeryDepartment of Surgery Medical College of Wisconsin Milwaukee WI Department of Surgery Baylor College of Medicine Houston TX Section of Hepatobiliary and Transplant Surgery University of Louisville School of Medicine Louisville KY Medstar Georgetown Transplant Institute Georgetown University Washington DC.
The incidence of hepatocellular carcinoma (HCC) is growing in the United States, especially among the elderly. Older patients are increasingly receiving transplants as a result of HCC, but the impact of advancing age on long-term posttransplant outcomes is not clear. To study this, we used data from the US Multicenter HCC Transplant Consortium of 4980 patients.
View Article and Find Full Text PDFReply.
Hepatology
October 2020
Dumont-UCLA (University of California, Los Angeles) Transplant and Liver Cancer Centers, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
Hepatology
December 2020
Dumont-UCLA (University of California, Los Angeles) Transplant and Liver Cancer Centers, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Background And Aims: The Organ Procurement and Transplantation Network recently approved liver transplant (LT) prioritization for patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are down-staged (DS) with locoregional therapy (LRT). We evaluated post-LT outcomes, predictors of down-staging, and the impact of LRT in patients with beyond-MC HCC from the U.S.
View Article and Find Full Text PDFPathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium.
Ann Surg
April 2020
Dumont-UCLA (University of California, Los Angeles) Transplant and Liver Cancer Centers, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Objective: The aim of the study was to determine the rate, predictors, and impact of complete pathologic response (cPR) to pretransplant locoregional therapy (LRT) in a large, multicenter cohort of hepatocellular carcinoma (HCC) patients undergoing liver transplantation (LT).
Background: LRT is used to mitigate waitlist dropout for patients with HCC awaiting LT. Degree of tumor necrosis found on explant has been associated with recurrence and overall survival, but has not been evaluated in a large, multicenter study.
Evaluation of Early Allograft Function Using the Liver Graft Assessment Following Transplantation Risk Score Model.
JAMA Surg
May 2018
Dumont-UCLA (University of California, Los Angeles) Transplant and Liver Cancer Centers, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles.
Importance: Early allograft dysfunction (EAD) following a liver transplant (LT) unequivocally portends adverse graft and patient outcomes, but a widely accepted classification or grading system is lacking.
Objective: To develop a model for individualized risk estimation of graft failure after LT and then compare the model's prognostic performance with the existing binary EAD definition (bilirubin level of ≥10 mg/dL on postoperative day 7, international normalized ratio of ≥1.6 on postoperative day 7, or aspartate aminotransferase or alanine aminotransferase level of >2000 U/L within the first 7 days) and the Model for Early Allograft Function (MEAF) score.
There's more than 1 way to split a liver and skin a cat.
Arch Surg
September 2011
Department of Surgery, Dumont-University of California, Los Angeles Transplant and Liver Cancer Centers, Pfleger Liver Institute, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.